A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT04244656 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
26
Enrollment
INDUSTRY
Sponsor class

Stopped Patients to be followed up in the CRSP-ONC-LTF study

Conditions

Interventions

Sponsor

CRISPR Therapeutics AG